• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Adaptimmune Provides Q4 and Full Year 2024 Business Update

    3/20/25 7:00:00 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAP alert in real time by email

    TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024;
    20 ATCs available; all manufacturing and supply goals achieved

    Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026

    Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs

    At the end of 2024, Adaptimmune had Total Liquidity1 of $152 million

    Evaluating all strategic options to maximize shareholder value

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today provided a Q4 and Full Year 2024 business update.

    Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is going very well and each step in delivering this important medicine: activating our treatment network; identifying biomarker eligible patients; exceptional manufacturing quality and turn-around times, strengthens our sarcoma platform capabilities for both Tecelra and for lete-cel. These results give us confidence in our strategy to build value from our sarcoma franchise and our path to profitability in 2027. In the context of the current capital markets, we are assessing all strategic options to enable us to achieve these goals."

    Tecelra launch momentum increasing – the first commercial product in Adaptimmune's sarcoma franchise

    • 20 Authorized Treatment Centers (ATCs) now accepting referrals
    • On track to have the full network of approximately 30 ATCs open by end of 2025
    • Apheresed 3 patients in 2024 and invoiced 2 with Q4 product revenue of $1.2m
    • Apheresed 10 patients in 2025 to date
    • Successful reimbursement with no denials to date
    • 100% success rate in manufacturing to date with no capacity constraints

    Lete-cel – the next product in Adaptimmune's sarcoma franchise

    • Pivotal trial met primary endpoint with 42% ORR including 6 complete responses (CTOS 2024)
    • On track to initiate rolling BLA submission in late 2025; approval anticipated in 2026
    • Lete-cel will expand the addressable patient population for sarcoma franchise

    Corporate updates

    • Executed on 29% reduction in headcount in Q1 2025 as part of approximately $300 million in aggregate cost savings over the next four years to enable goal of achieving operating profitability during 2027
    • Implemented additional cost reduction for the PRAME and CD70 programs. The Company anticipates this will generate an additional $75m to $100m in aggregate cost savings over the next 4 years
    • Engaged TD Cowen to evaluate strategic options for the Company and for all its programs

    Upcoming milestones

    • Updates on Tecelra Launch momentum (ATCs, number of patients apheresed)
    • Initiate rolling BLA for lete-cel to treat synovial sarcoma and MRCLS in Q4 2025

    Going Concern

    • Our 2024 Annual Report on Form 10-K (the "Annual Report"), which the Company plans to file on Monday, March 24, will disclose that there is substantial doubt about our ability to continue as a going concern. We are continuing to implement cost reduction measures and explore the strategic options outlined above. More information on these topics will be provided on today's webcast and in the Annual Report.

    Total Liquidity (a non-GAAP financial measure)

    • Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents, which reconciles to Total Liquidity as follows (in thousands):

    December 31,
    December 31,

    2024
    2023
    Cash and cash equivalents$91,139
    $143,991
    Marketable securities - available-for-sale debt securities
    60,466

    2,947
    Total Liquidity$151,605
    $146,938

     

    • The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage.

    Presentations, publications, and awards

    • Adaptimmune had four poster presentations accepted at the upcoming Society for Immunotherapy of Cancer (SITC) Spring Conference (March 12-14, 2025):
      1. "Emerging T-Cell Receptor T-Cell Therapies for Solid Tumors: Differentiating from CAR-T." Locke et al.
      2. "Long-term survival of patients with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma who received afamitresgene autoleucel T-cell receptor T-cell therapy in SPEARHEAD-1." D'Angelo et al. (TANDEM 2025 encore)
      3. "Translational analyses reveal mechanisms of afami-cel's anti-tumor activity in synovial sarcoma." Dupont et al. (SITC 2024 encore)
      4. "Primary analysis of the pivotal IGNYTE-ESO trial of letetresgene autoleucel in patients with synovial sarcoma or myxoid/round cell liposarcoma." D'Angelo et al. (CTOS 2024 encore)
    • Lete-cel MRCLS pilot study 208469 was published in the Journal of Clinical Oncology and "Melanoma-associated antigen A4: a cancer testis antigen as a target for adoptive T-cell receptor T-cell therapy" has been published in Cancer Treatment Reviews.
    • In December last year, Forbes Magazine named Tecelra as one of the 6 Revolutionary Tech Developments that Define 2024.
    • In March 2025, Adaptimmune was awarded the 2025 Life Sciences PA (Pennsylvania) Patient Impact Award and was recognized as one of Fast Company's Most Innovative Companies of 2025. Both awards recognize companies that are transforming industries and improving lives through groundbreaking innovation.
    • A virtual KOL event featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) was held on November 18, 2024 to discuss the unmet need and current treatment landscape for patients with sarcoma, including synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS). Replay available: Adaptimmune Virtual KOL Event - LifeSci Events

    Today's Webcast Details
    A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.

    About Adaptimmune
    Adaptimmune is an integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.

    Forward-Looking Statements
    This release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

    Adaptimmune Contact

    Investor Relations
    Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
    M : +1 215 460 8920
    [email protected]

    Media Relations
    Dana Lynch, Senior Director of Corporate Communications
    M: +1 267 990 1217
    [email protected]


    1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/245279

    Get the next $ADAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAP

    DatePrice TargetRatingAnalyst
    7/30/2024$4.00Buy
    H.C. Wainwright
    5/30/2024$3.15Sector Outperform
    Scotiabank
    3/24/2023$3.60Buy
    Bryan Garnier
    1/3/2023$5.00Neutral → Buy
    Guggenheim
    11/9/2022$9.00Neutral → Buy
    Mizuho
    9/22/2021$6.00 → $7.00Equal-Weight
    Wells Fargo
    9/13/2021$6.00 → $7.00Market Perform
    SVB Leerink
    9/7/2021$5.00 → $6.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:35:34 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:34:48 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Patient Supply Officer Lunger John

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:33:25 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Leadership Updates

    Live Leadership Updates

    See more

    $ADAP
    SEC Filings

    See more
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13966. Call in information is as follows: 1-8

      3/12/25 4:54:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      5/1/25 4:15:32 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adaptimmune Therapeutics plc

      DEF 14A - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/25/25 8:02:51 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Adaptimmune Therapeutics plc

      S-3 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

      4/18/25 4:32:27 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Financials

    Live finance-specific insights

    See more
    • Adaptimmune Reports Q3 2024 Financial and Business Updates

      Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million

      11/13/24 4:05:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Reports Q2 2024 Financial and Business Updates

      Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive ordersAt the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 millionPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) tod

      8/12/24 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

      Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*0

      8/1/24 8:20:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Adaptimmune Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00

      7/30/24 6:31:41 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptimmune Therapeutics with a new price target

      Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15

      5/30/24 7:25:43 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bryan Garnier initiated coverage on Adaptimmune Therapeutics with a new price target

      Bryan Garnier initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $3.60

      3/24/23 9:09:04 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      11/13/24 9:04:55 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13D/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      4/2/24 8:38:07 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc (Amendment)

      SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

      3/26/24 11:59:28 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care